References
- Kumar, S. K.; Rajkumar, S. V.; Dispenzieri, A.; et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5), 2516–2520.
- Scott, L. J.; Lyseng-Williamson, K. A. Lenalidomide: A review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2011, 71(5), 625–649.
- Singhal, S.; Mehta, J.; Desikan, R.; et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341(21), 1565–1571.
- Elkinson, S.; McCormack, P. L. Pomalidomide: First global approval. Drugs 2013, 73(6), 595–604.
- Galustian, C.; Dalgleish, A. G. Pomalidomide: TNF-α production inhibitor treatment of multiple myeloma treatment of myelofibrosis. Drugs of the Future 2011, 36(10), 741–750.
- Ge, C.; Muller, G. W.; Chen, R.; Saindane, M. T. Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds. US Patent US20070004920A1, 2007.
- Zhu, X. X.; Giordano, T.; Yu, Q. S.; Holloway, H. W.; Perry, T. A.; Lahiri, D. K.; Brossi, A.; Greig, N. H. Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-α inhibitory activity. J. Med. Chem. 2003, 46(24), 5222–5229.
- Perino, S.; Contino-Pepin, C.; Satchi-Fainaro, R.; Butterfield, C.; Pucci, B. Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties. Bioorg. Med. Chem. Lett. 2004, 14(2), 421–425.
- Ambrozak, A.; Guetschow, M. Preparation of phthalamic acid derivatives and ring closure to phthalimidobarbituric acids. J. Heterocycl. Chem. 2007, 44(6), 1259–1263.
- Chuansheng, G.; Roger, C. Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds. CN Patent CN101253163A, 2008.
- Webster, S. P.; Seckl, J. R.; Walker, B. R.; Ward, P.; Pallin, T. D.; Dyke, H. J.; Perrior, T. R. Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders. WO Patent WO2010/146338A1, 2010.
- Palmer, B. D.; Ching, L. M. (2,6-Dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives. WO Patent WO2008007979A1, 2008.